NEW YORK, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Veteran business journalist Jill Bennett joins Dr. Isa Odidi, CEO, Intellipharmaceutics International Inc. (IPCI), to discuss the company's industry, strategy, financials and positioning.
Click here to view video:
http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=44144&k=914A413F6782D865D87CDFC970083297
In 1998, Dr. Isa Odidi, together with Dr. Amina Odidi, founded Intellipharmaceutics Ltd., a predecessor of publicly-traded Intellipharmaceutics International Inc. From 1995 to 1998, Isa held positions, first as Director, then as Vice President of Research of Drug Development and New Technologies, at Biovail Corporation International (now Biovail Corporation), a very successful drug delivery company. Prior to 1995, Isa held senior positions in academia and in the pharmaceutical and health care industries. Isa and Amina are prolific inventors and have numerous patents and patent applications to their credit. Their work has been cited in textbooks and they have published over a hundred scientific and medical papers, articles, and textbooks. Isa currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine in California. Isa received his B.Sc. degree in Pharmacy, and his M.Sc. in Pharmaceutical Technology and his Ph.D. in Pharmaceutics from the University of London. He is also a graduate of the Western Executive Management Program and obtained his MBA from the Rotman School of Management at the University of Toronto.
About Intellipharmaceutics Inc.:
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel or generic controlled release and targeted release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a unique and validated multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, pain and infection. The Company has three products under review with the FDA for the purpose of obtaining regulatory approval.
Intellipharmaceutics' lead generic product under development is Dexmethylphenidate XR (dexmethylphenidate hydrochloride), a generic version of Focalin XR®, which is an extended-release capsule for the treatment of Attention Deficit Hyperactivity Disorder. In 2008, Focalin®, including Focalin XR®, had U.S. sales of approximately U.S. $350 million.
Intellipharmaceutics' lead non-generic product under development is Rexista™ oxycodone, an abuse- and alcohol-deterrent controlled-release oral formulation of controlled-release oxycodone hydrochloride for the relief of pain. Rexista™ oxycodone is a unique dosage form designed to be deterrent to some of the well-documented abuses associated with currently marketed oxycodone products, such as abuse of these drugs by nasal inhalation when crushed or powdered and by injection when combined with solvents. Rexista™ oxycodone is also designed to resist release of the entire dose when consumed with alcohol, a significant problem with some opioid drugs. In 2008, oxycodone had U.S. sales of approximately U.S. $2 billion.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.
The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839